The European Society for Medical Oncology (ESMO) Congress 2025 took place in Berlin, Germany, marking its 50th anniversary. Fast Five brings you key insights from leading experts, captured live at the Congress.
In this episode, Nicolas Girard, Head of Medical Oncology, Institut Curie, France, discusses the latest developments in non-small cell lung cancer (NSCLC), with a focus on new trial data and updated clinical guidance.
- The HARMONi-6 trial and its exploration of new first-line treatment options for advanced NSCLC
- Key updates from the ESMO guidelines for early and locally advanced NSCLC and what clinicians should pay attention to
- Challenges in translating emerging trial data, such as HARMONi-6 and OptiTROP-Lung04, into real-world clinical practice
The EMJ Oncology Journal is out today, delivering full, in-depth coverage of all the key moments from the ESMO Congress, alongside peer-reviewed articles, interviews, and an informative infographic.
Disclosure: Nicolas has received grants/support to institution from Abbvie, Amgen, AstraZeneca, BeOne, Boehringer Ingelheim, Bayer, BioNTech, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, J&J, Lilly, Sivan, Tahio; consulting fees from Abbvie, Accord, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi-Sankyo, Ipsen, J&J, Lilly, Merck Sharp & Dohme, Natera, Pfizer, Pharmamar, Pierre Fabre, Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Amgen, AstraZeneca, BeOne, Bristol Myers Squibb, Daiichi-Sankyo, J&J, Merck Sharp & Dohme, Novocure; and support for attending meetings and/or travel from Bristol Myers Squivv, J&J, and Pierre-Fabre.
